Contact sales

Bring research to life

Ossium supports customers from discovery through commercialization by supplying both clinical and research grade human cells. We’ve invested in building a state-of-the-art production facility, a team with deep CMC expertise, and comprehensive donor qualification capabilities so that you can focus on your research goals.

OssiGraft™ Viable Bone Matrix Allografts

Viable bone matrix allografts for the repair, replacement, and reconstruction of musculoskeletal defects

GMP Human Mesenchymal Stem Cells

Ossium’s GMP MSCs are derived from the vertebral bodies of organ donors and are phenotypically and functionally equivalent to MSCs obtained from aspirated bone marrow.

GMP Human Selected CD34+ Cells

Ossium’s GMP CD34+ cells are aseptically selected from vertebral body bone marrow by density gradient and positive immunomagnetic separation.

RUO Mesenchymal Stem Cells (MSCs)

Ossium’s MSCs are derived from the vertebral bodies of organ donors and are phenotypically and functionally equivalent to MSCs obtained from aspirated bone marrow. Intended for research use only.

RUO Human Selected CD34+ Cells

Human CD34+ cells, positively selected from HPC, Marrow and enriched for hematopoietic stem cells (HSCs). Intended for research use only.

HPC, Marrow

Cryopreserved whole bone marrow derived from organ donor vertebral bodies using Ossium’s proprietary processing methods, contains Hematopoietic Progenitor Cells (HPCs).

Ossium Health has maintained CLIA certification since 2019. The Centers for Medicare & Medicaid Services (CMS) regulates all clinical laboratory testing performed on humans in the U.S. through the Clinical Laboratory Improvement Amendments (CLIA), which covers ~260,000 laboratory entities.

Partner With Us

Let's work together to revolutionize treatment for patients suffering from hematologic diseases, organ rejection, and musculoskeletal defects.